Multi-institutional review of sinonasal and skull base chondrosarcoma: 20-year experience

Head Neck. 2022 Dec;44(12):2686-2695. doi: 10.1002/hed.27178. Epub 2022 Sep 2.

Abstract

Background: Chondrosarcomas of the sinonasal cavity and skull base are uncommon malignancies. We sought to provide long-term outcomes at two tertiary care centers.

Methods: Patients with chondrosarcoma treated between 2000 and 2021 were included. The primary outcomes were overall survival (OS) and disease-specific survival (DSS).

Results: Thirty-eight patients met inclusion criteria. Fourteen patients had sinonasal (36.8%), 7 petroclival (18.4%), and 17 other primary skull base lesions (44.7%). Twenty-eight patients (73.7%) underwent radiation with an average dose of 67.3 ± 15.1 Gy. Eighteen patients (47.4%) required revision surgery for recurrence. 1, 5, and 10-year OS were 97.3%, 93.1%, and 74.7%. DSS at 5- and 10-year survival was 95.7%. Adjuvant radiation was associated with improved OS (HR: 0.12; 95% CI: 0.02-0.75, p = 0.023).

Conclusion: We present our experience over the last 20 years treating chondrosarcomas. Favorable survival outcomes can be achieved but recurrence requiring repeat resection is common.

Keywords: chondrosarcoma; clivus; sinonasal; sinus; skull base; survival.

Publication types

  • Multicenter Study

MeSH terms

  • Chondrosarcoma* / surgery
  • Humans
  • Radiotherapy, Adjuvant
  • Retrospective Studies
  • Skull Base / pathology
  • Skull Base Neoplasms* / surgery
  • Treatment Outcome